OakChart

Fortress Biotech Inc

FBIOHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.01+0.10 (5.24%)
2026-11-12 01:01 CET
Market cap
63.70 USD m
Revenue, TTM
68.47 USD m
Net income, TTM
103.37 USD m
Free cash flow, TTM
120.28 USD m
EPS diluted, TTM
2.66
P/E
0.76
Compare

Price

FBIO against its 20, 50 and 200-day averages
2050200beat
2.002.503.003.501.2M2.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FBIOclose 2.0120-day 1.9350-day 2.17200-day 2.732.0152w low

55.6% under the 52-week high of 4.53 on 9 Jan 2026. 52-week low 1.79 on 5 Nov 2026. Last 15 sessions, 15.6% high to low

Volume 1.16× normal · the line is the 50-bar volume average

Profile

FBIO
52-week range, 8% of the way up
1.794.53

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Employees78
IPONov 17, 2011
Beta1.26
ATR, 14d0.10
Rel volume1.16
Short float20.01%
Insider own30.90%
Inst own24.92%

Snapshot

6 groups

Valuation

Index-
Market Cap67.04M
Enterprise Value-34.27M
Income103.37M
Sales68.47M
Book/sh4.93
Cash/sh5.89
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees78
IPONov 17, 2011

Ratios

P/E0.76
Forward P/E-
PEG-
P/S0.98
P/B0.41
P/C0.34
P/FCF0.56
EV/EBITDA-
EV/Sales-0.50
Quick Ratio3.83
Current Ratio3.96
Debt/Eq0.32
LT Debt/Eq0.28
Option/ShortYes / Yes

Earnings

EPS (ttm)2.66
EPS next Y-1.00
EPS next Q-0.27
EPS this Y3742.86%
EPS next Y-139.22%
EPS next 5Y-
EPS past 3/5Y83.35% 62.98%
Sales past 3/5Y-5.83% 6.77%
EPS Y/Y TTM401.39%
Sales Y/Y TTM15.46%
EPS Q/Q-117.40%
Sales Q/Q14.04%
EarningsAug 13 AMC
EPS/Sales Surpr.60.00% 2.28%

Ownership

Insider Own30.90%
Insider Trans0.00%
Inst Own24.92%
Inst Trans-1.34%
ROA46.92%
ROE107.48%
ROIC53.19%
Gross Margin58.88%
Oper. Margin-42.86%
Profit Margin150.97%
SMA204.23%
SMA50-7.28%
SMA200-26.26%
Trades-

Technical

Shs Outstand33.31M
Shs Float23.04M
Short Float20.01%
Short Ratio13.99
Short Interest4.61M
52W High4.53 -55.63%
52W Low1.79 12.29%
Volatility6.64% 4.99%
ATR (14)0.10
RSI (14)50.19
Beta1.26
Rel Volume1.16
Avg Volume329.50K
Volume382,214

Performance

Perf Week2.03%
Perf Month3.08%
Perf Quarter-32.55%
Perf Half Y-9.87%
Perf YTD-45.08%
Perf Year-25.00%
Perf 3Y53.44%
Perf 5Y-96.19%
Perf 10Y-95.06%
Recom1.00
Target Price5.00
Prev Close1.91
Price2.01
Change %5.24%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Mar 15, 2024ResumedRROTH MKMBuy$10+397.5%
Aug 04, 2022InitiatedLLadenburg ThalmannBuy$6+198.5%
Oct 02, 2020InitiatedTThe Benchmark CompanyBuy$9+347.8%
Dec 18, 2019InitiatedBB. Riley FBRBuy$9+347.8%
Feb 28, 2018InitiatedBB. Riley FBR, Inc.Buy$10+397.5%
Jul 11, 2017InitiatedRRodman & RenshawBuy$11+447.3%
Mar 22, 2017InitiatedJJMP SecuritiesMkt Outperform
Oct 03, 2016InitiatedRROTH CapitalBuy$9+347.8%

Peers

Mkt cap
TickerCompanyMkt cap
VRCAVerrica Pharmaceuticals Inc67.17M
PTHSPelthos Therapeutics Inc36.92M
SLGLSol-Gel Technologies Ltd207.57M
ARQTArcutis Biotherapeutics Inc3.59B
ROIVRoivant Sciences Ltd30.32B
HRTXHeron Therapeutics Inc68.36M
BFRIBiofrontera Inc13.92M
EOLSEvolus Inc491.11M
ETONEton Pharmaceuticals Inc1.97B
AYTUAytu BioPharma Inc19.67M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) (GlobeNewswire) +5.24%
  • Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 (GlobeNewswire) -6.60%
  • Journey Medical Corporation to Participate in September 2026 Investor Conferences (GlobeNewswire)
  • Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Fortress Biotech: Q2 Earnings Snapshot (Associated Press) +8.36%
  • Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
  • Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.36%
  • Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
  • Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing (GlobeNewswire)
  • Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
  • Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
  • Fortress Biotech: Q1 Earnings Snapshot (Associated Press)
  • Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
  • Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.080-0.200-0.08018.7218.301
2026Q12026-05-142.820-0.2202.82116.0416.341
2025Q42026-03-31-0.1500.110-0.19816.0826.172
2025Q32025-11-140.110-0.4200.11117.6321.022
2025Q22025-08-140.450-0.3600.44816.4114.532
2025Q12025-05-15-0.480-0.495-0.48113.1411.622
2024Q42025-03-31-0.170-0.753-0.34615.1214.583
2024Q32024-11-14-0.760-0.595-0.76414.6332.222
2024Q22024-08-13-0.730-1.223-0.72814.9014.753
2024Q12024-05-15-1.030-1.730-1.03413.0314.133
2023Q42024-03-28-0.780-1.645-0.74819.9415.122
2023Q32023-11-14-0.940-3.206-14.10934.7514.505
2023Q22023-08-14-3.600-3.413-3.63117.3915.464
2023Q12023-05-15-3.150-3.000-3.17112.4317.334
2022Q42023-03-30-4.500-3.330-3.65816.4022.065
2022Q32022-11-14-3.750-4.050-3.77616.5320.846

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-20.700-17.100-20.70016.4822.30
2017FY-24.150-30.550-24.080187.58189.6
2018FY-29.100-29.400-29.84726.88246.2
2019FY-10.950-11.130-10.95636.6336.96
2020FY-9.750-10.900-9.69245.6043.83
2021FY-11.850-5.500-11.87968.7989.50
2022FY-14.550-13.125-14.61275.7477.97
2023FY-8.470-7.745-8.46684.5179.70
2024FY-2.690-3.507-2.68957.6857.13
2025FY-0.0700.315-0.07063.2673.34
2026FY-2.550--78.79
2027FY--1.000--113.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0410021.5821.5821.58
2026Q3S2026-08-2110121.5821.5821.58
2026Q3S2026-08-1410022.2922.2922.29
2026Q3S2026-08-1310022.2922.2922.29
2026Q3S2026-05-1510022.2922.2922.29
2026Q3S2026-04-0610022.4922.4922.49
2026Q3R2026-11-04100-0.27-0.27-0.27
2026Q3R2026-08-21101-0.27-0.27-0.27
2026Q3R2026-08-14100-0.15-0.15-0.15
2026Q3R2026-08-13100-0.15-0.15-0.15
2026Q3R2026-07-29100-0.15-0.15-0.15
2026Q3R2026-05-15110-0.15-0.15-0.15
2026Q3R2026-04-06100-0.16-0.16-0.16
2026Q3E2026-11-04100-0.27-0.27-0.27

Estimate history

EPS, annual-24.08-29.847-10.956-9.692-11.879-14.612-8.466-2.689-0.0672.6566
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.728-0.764-0.346-0.4810.4480.111-0.1982.821-0.078
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual17.24526.88236.62945.59968.79175.74384.51357.67563.26268.47
Period201720182019202020212022202320242025TTM
Sales, quarterly14.89614.62915.1213.13916.41317.63116.07916.03818.718
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.3993.8564.9356.3256.7627.36615.09327.90931.36433.311
Period201720182019202020212022202320242025MRQ
Shares, quarterly22.58727.58527.90929.55529.75331.00531.36433.18733.311
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue68.4763.2657.6784.5175.7468.7945.6036.6326.88
Cost of Goods Sold Incl. D&A28.1525.5925.3428.8933.8834.7116.8712.457.52
Gross Profit40.3137.6832.3355.6241.8634.0828.7324.1819.36
Selling, General and Administrative Excl. Other69.66107.90143.57194.87245.42213.08123.00134.99139.36
Research and Development1.1911.9056.88106.07134.88128.8764.1181.3387.38
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-29.34-70.22-111.24-139.24-203.56-179.00-94.27-110.82-120.00
Interest Expense9.6310.119.9312.5213.6415.3115.3311.8510.34
Unusual Expense-8.02-14.703.381.47-1.13-29.31-5.23-18.451.64
Net Income Before Taxes145.86-33.53-120.54-153.63-213.46-164.35-102.85-101.66-130.80
Income Taxes4.66-0.620.310.520.450.470.140.000.00
Consolidated Net Income141.19-32.91-120.86-154.15-213.91-164.83-102.98-101.66-130.80
Net Income From Continuing Operations111.826.82-46.00-60.64-86.58-64.70-46.53-39.96-73.01
Net Income103.37-1.88-55.89-68.67-86.58-64.70-46.53-39.96-86.48
EPS (Recurring)3.07-0.44-2.58-8.34-14.75-15.65-10.45-14.50-29.45
EPS (Basic, Before Extraordinaries)3.30-0.07-2.69-8.47-14.61-11.88-9.69-10.96-29.85
EPS (Diluted)2.66-0.07-2.69-8.47-14.61-11.88-9.69-10.96-29.85
EBITDA-22.83-63.62-103.93-131.17-194.21-172.21-88.94-106.17-117.94
Non-Operating Income (Expense)176.8132.094.00-0.402.610.651.522.561.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.6722.7025.7713.4518.1614.229.8213.1915.01
Price To Earnings Ratio0.720.72-------
Price To Sales Ratio1.421.610.730.290.772.975.013.841.39
Gross Margin58.8859.5656.0665.8255.2649.5462.9966.0072.03
Operating Margin-42.86-111.00-192.87-164.76-268.76-260.21-206.74-302.54-446.38
Net Margin150.97-2.97-96.91-81.25-114.30-94.06-102.03-109.09-321.70
Shares Outstanding33.3131.3627.9115.097.376.766.334.943.86
Market Capitalization63.7063.7055.9044.6370.91253.59300.76190.2548.32

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue18.7216.0416.0817.6316.4113.1415.1214.63
Cost of Goods Sold Incl. D&A7.217.446.606.916.095.985.805.38
Gross Profit11.518.609.4810.7210.327.169.319.24
Selling, General and Administrative Excl. Other21.5216.3414.2717.5346.7929.4836.6631.34
Research and Development0.810.54-0.370.218.133.949.949.45
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.01-7.74-4.79-6.81-36.47-22.32-27.34-22.09
Interest Expense1.483.372.042.742.522.812.596.21
Unusual Expense0.007.08-15.100.000.350.05-3.45-0.02
Net Income Before Taxes0.92142.29-6.218.85-11.65-24.69-25.98-26.62
Income Taxes0.325.13-0.820.030.000.000.340.07
Consolidated Net Income0.60137.16-5.408.83-11.65-24.69-26.32-26.69
Net Income From Continuing Operations-0.47110.37-3.945.8515.49-10.58-6.76-12.87
Net Income-2.48108.36-6.203.6713.36-12.71-9.65-15.04
EPS (Recurring)-0.082.95-0.530.110.46-0.48-0.43-0.76
EPS (Basic, Before Extraordinaries)-0.083.44-0.200.130.50-0.48-0.35-0.76
EPS (Diluted)-0.082.82-0.200.110.45-0.48-0.35-0.76
EBITDA-8.48-6.04-3.16-5.16-34.83-20.64-25.74-20.72
Non-Operating Income (Expense)12.40160.49-14.4818.4127.690.480.511.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.141.391.943.2016.796.2912.795.19
Price To Earnings Ratio0.72-------
Price To Sales Ratio1.421.621.811.960.940.710.980.46
Gross Margin61.5053.6358.9760.8062.8654.4861.6163.19
Operating Margin-53.46-48.25-29.78-38.63-222.22-169.85-180.85-151.04
Net Margin-13.23675.68-38.5520.8481.37-96.77-63.84-102.81
Shares Outstanding33.3133.1931.3631.0129.7529.5527.9127.58
Market Capitalization63.7086.60113.60109.9455.0043.0655.9038.71

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments79.3857.2680.93178.27305.74233.35136.8683.11130.95
Short Term Receivables29.9410.4015.3928.3523.7924.6714.407.598.38
Inventories9.6214.4310.2114.169.861.400.860.680.17
Other Current Assets4.898.2810.509.667.076.724.1319.8243.68
Total Current Assets123.8490.37117.02230.43346.46266.15156.25111.21183.18
Net Property, Plant & Equipment14.8217.1223.5033.0134.0732.4133.9112.027.12
Total Investments and Advances18.881.552.442.692.2219.2127.7216.0717.40
Intangible Assets27.6131.8620.2927.2012.5514.637.381.420.88
Other Assets0.403.324.280.971.201.011.160.2837.37
Total Assets185.55144.22167.53294.30396.50333.41226.42140.99245.95
Short Term Debt Incl. Current Port. of LT Debt2.133.259.4514.687.436.379.0019.0813.23
Accounts Payable14.2431.6434.8157.2447.4311.4110.0517.8610.00
Income Tax Payable0.360.930.840.720.340.14---
Other Current Liabilities33.0235.5839.8055.0745.8433.8426.5618.6848.21
Total Current Liabilities49.7471.4084.91127.72101.0451.7645.6255.6171.44
Long Term Debt65.0972.7179.14114.7167.5582.70101.1560.4249.27
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities8.531.761.891.852.031.957.135.214.74
Total Liabilities123.36145.87165.94244.28170.63136.41153.89121.25125.45
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity49.8722.7322.5441.72108.67100.3326.211.8552.57
Total Shareholders Equity49.8722.7422.5441.72108.67100.3426.211.8552.57
Accumulated Minority Interest12.31-24.38-20.968.30117.2096.6646.3217.8967.93
Total Equity62.18-1.641.5950.02225.88197.0072.5319.74120.50
Total Liabilities & Stockholders Equity185.55144.22167.53294.30396.50333.41226.42140.99245.95
Book Value Per Share1.590.811.495.6616.0715.865.310.4815.46
Tangible Book Value Per Share0.71-0.330.151.9714.2113.553.820.1115.21
Full-Time Employees78101186187173111938868
Price to Book Ratio0.392.640.111.152.333.007.261.285.46
Return on Assets4.13-29.51-26.26-25.06-17.84-16.62-21.75-37.74-30.98
Return on Equity18.77-203.16-188.71-115.13-61.91-73.53-284.75-268.30-141.77
Return on Invested Capital5.93-48.19-59.63-55.34-36.72-25.42-31.37-138.86-65.67
Quick Ratio2.301.061.261.693.335.113.411.992.56
Current Ratio2.491.271.381.803.435.143.432.002.56

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income141.19-32.91-120.86-154.15-213.91-164.83-102.98-101.66-130.80
Depreciation6.516.607.318.079.356.795.334.652.06
Other Funds (Non Cash)-14.16-19.9341.4830.3725.755.1218.766.8924.16
Funds from Operations133.55-46.24-72.06-115.71-178.81-152.91-78.90-90.12-104.58
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-13.19-25.10-8.13-12.52-0.7136.37-4.78-4.845.74
Income Taxes Payable4.20-0.580.090.120.380.340.14--
Cash from Operating Activities120.36-71.34-80.19-128.22-179.52-116.54-83.68-94.96-98.85
Capital Expenditures-0.080.00-15.00-8.10-23.05-16.35-7.16-9.39-9.36
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.001.170.006.000.1356.860.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.0017.6018.40
Purchase of Investments0.000.000.000.000.000.000.00-5.00-52.60
Sale Or Maturity of Investments0.000.000.000.000.000.000.0022.6071.00
Other Uses0.000.000.00-0.010.000.000.00-1.200.00
Other Sources2.878.960.000.000.000.000.0013.099.78
Cash from Investing Activities2.7910.12-15.00-2.10-22.9340.51-7.1620.1018.82
Cash Dividends Paid-0.33-0.66-4.71-8.77-8.78-8.78-6.75-2.56-2.34
Change in Capital Stock9.0184.3783.9381.3041.67172.81213.79135.9237.97
Repurchase of Common Pref Stock-14.34-0.270.00-0.40-1.190.00-0.070.000.00
Sale of Common Pref Stock23.3484.6383.9381.7042.86172.81213.86135.9237.97
Proceedsfrom Stock Options74.0581.6883.3981.7042.69172.53213.60135.7937.78
Issuance or Reduction of Debt, Net-9.64-0.70-8.58-39.7944.25-9.73-34.1213.3615.03
Change in Long Term Debt-9.64-0.70-8.58-39.7944.25-9.73-34.1213.3615.03
Issuance of Long Term Debt0.000.0043.6742.5352.116.9155.5513.3619.43
Reduction of Long Term Debt-9.64-0.70-52.25-82.32-7.86-16.64-89.670.00-4.41
Net Financing Active Other Cash Flow0.000.000.000.00-1.70-5.30-0.500.000.00
Other Financing Activities Uses0.000.000.000.00-1.70-5.30-0.500.000.00
Cash from Financing Activities-0.9683.0070.6432.7475.44148.99172.41146.7150.65
Net Change in Cash122.1921.79-24.55-97.59-127.0172.9781.5671.85-29.38
Free Cash Flow120.28-71.34-80.19-128.29-202.57-121.11-85.61-97.31-105.93
Preferred Dividends (Cash Flow)-0.00-4.02-8.03-8.03-8.03-6.51-2.56-2.34
Price to Free Cash Flow0.81--------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments196.58255.8479.3886.2274.3991.34
Short Term Receivables36.7525.5129.9418.1216.2018.33
Inventories8.169.299.6211.8212.8512.50
Other Current Assets4.024.844.892.346.964.73
Total Current Assets245.51295.48123.84118.50110.40126.90
Net Property, Plant & Equipment13.7714.2514.8214.9315.5216.10
Total Investments and Advances30.6719.9318.881.221.221.22
Intangible Assets25.5126.4827.6128.6729.7330.80
Other Assets1.260.740.4018.083.023.05
Total Assets316.71356.87185.55181.41159.90178.07
Short Term Debt Incl. Current Port. of LT Debt7.254.722.137.755.894.03
Accounts Payable11.8614.1414.2418.7720.1927.82
Income Tax Payable5.185.420.361.000.980.95
Other Current Liabilities37.7479.1133.0226.5430.4640.87
Total Current Liabilities62.02103.3949.7454.0757.5273.67
Long Term Debt46.0748.9165.0960.5463.3370.20
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.542.208.531.621.661.71
Total Liabilities110.63154.50123.36116.22122.51145.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity164.14162.2149.8755.8643.9222.25
Total Shareholders Equity164.14162.2149.8755.8643.9222.25
Accumulated Minority Interest41.9540.1712.319.32-6.5410.24
Total Equity206.09202.3762.1865.1937.3832.49
Total Liabilities & Stockholders Equity316.71356.87185.55181.41159.90178.07
Book Value Per Share4.934.891.591.801.480.75
Tangible Book Value Per Share4.164.090.710.880.48-0.29
Full-Time Employees--78---
Price to Book Ratio0.391.752.032.502.471.92
Return on Assets46.9247.774.132.58-9.64-24.02
Return on Equity107.48138.5418.7710.35-47.67-181.84
Return on Invested Capital-0.2252.28-3.425.0314.44-11.45
Quick Ratio3.832.772.301.971.701.55
Current Ratio3.962.862.492.191.921.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income0.60137.16-5.408.83-11.65-24.69
Depreciation1.531.701.631.651.641.68
Other Funds (Non Cash)-7.779.20-3.54-12.06-10.776.43
Funds from Operations-5.64148.06-7.30-1.58-20.78-16.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-53.6455.79-10.80-4.53-6.78-2.98
Income Taxes Payable-0.245.06-0.650.020.030.02
Cash from Operating Activities-59.28203.85-18.11-6.11-27.56-19.56
Capital Expenditures-0.080.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.001.17
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.002.876.090.00
Cash from Investing Activities-0.080.000.002.876.091.17
Cash Dividends Paid0.000.00-0.17-0.17-0.17-0.17
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock0.09-12.905.8715.949.6252.93
Repurchase of Common Pref Stock0.00-14.340.000.00-0.12-0.15
Sale of Common Pref Stock0.091.445.8715.949.7353.08
Proceedsfrom Stock Options0.090.0767.006.890.047.75
Issuance or Reduction of Debt, Net0.00-14.495.56-0.70-4.93-0.62
Change in Long Term Debt0.00-14.495.56-0.70-4.93-0.62
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-14.495.56-0.70-4.93-0.62
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.09-27.3911.2715.074.5252.14
Net Change in Cash-59.27176.46-6.8411.83-16.9533.74
Free Cash Flow-59.36203.85-18.11-6.11-27.56-19.56
Price to Free Cash Flow0.810.71----

Revenue breakdown

Accutane2024: 19.41M 2025: 12.88M
Emrosi2025: 14.75M
Foam Franchise Products2024: 6.65M 2025: 5.86M
Other Legacy Product2024: 3.96M 2025: 2.74M
Qbrexza2024: 25.11M 2025: 25.01M
United States2024: 55.13M 2025: 61.24M
Avenue Therapeutics, Inc2025: 1.40M
Checkpoint2024: 41.00K
Consolidation, Policy2024: -1.54M 2025: -1.40M
Fortress Biotech Inc2024: 1.50M
Journey2024: 55.13M 2025: 61.24M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3020.01%4.6M23.0M407.89K
2026-10-1519.63%4.5M23.0M454.29K
2026-09-3021.26%4.9M23.0M512.33K
2026-09-1522.16%5.1M23.1M574.56K
2026-08-3123.67%5.4M23.0M604.33K
2026-08-1424.24%5.6M23.0M610.92K
2026-07-3125.25%5.8M22.9M501.68K
2026-07-1523.49%5.4M22.9M462.52K
2026-06-3023.16%5.3M22.9M451.33K
2026-06-1522.45%5.1M22.9M424.35K
2026-05-2922.53%5.1M22.6M419.75K
2026-05-1521.61%4.9M22.6M676.87K
2026-04-3019.09%4.6M24.4M718.74K
2026-04-1518.42%4.5M24.7M776.84K
2026-03-3116.99%4.4M25.7M1.01M
2026-03-1317.29%4.3M24.7M1.05M
2026-02-2718.13%4.5M24.7M1.02M
2026-02-1317.42%4.3M24.7M737.99K
2026-01-3018.53%4.6M24.7M703.29K
2026-01-1518.15%4.5M24.7M680.31K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.041.6531030.000.197-0.0070.001
call5.000.000.050.103.8137.000.000.110-0.0110.001
call7.500.004.900.004.9380.000.000.092-0.0140.001
put2.500.301.300.707.92544.000.00-0.791-0.0070.001
put5.000.605.500.000.0000.000.00-0.891-0.0120.001
put7.503.107.900.000.0000.000.00-0.908-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-29SCHEDULE 13G/ASEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-018-KCurrent report2026-09-30SEC
2026-09-01SCHEDULE 13GSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-238-KCurrent report2026-06-17SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-308-KCurrent report2026-03-30SEC
2026-03-20SCHEDULE 13D/ASEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-18SEC
2026-02-238-KCurrent report2026-02-22SEC
2026-01-138-KCurrent report2026-01-13SEC
2026-01-064Statement of changes in beneficial ownership of securities2026-01-02SEC
2026-01-06SCHEDULE 13D/ASEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-01SEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-01SEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-01SEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-02SEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-01SEC
2026-01-054Statement of changes in beneficial ownership of securities2026-01-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.12%
Opaleye Management Inc.2.68%
MACKENZIE FINANCIAL CORP1.59%
GSA CAPITAL PARTNERS LLP1.38%
ACADIAN ASSET MANAGEMENT LLC1.38%
SHIKIAR ASSET MANAGEMENT INC0.92%
GEODE CAPITAL MANAGEMENT, LLC0.86%
BlackRock, Inc.0.68%
TWO SIGMA INVESTMENTS, LP0.64%
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.53%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.10%
VANGUARD EXTENDED MARKET INDEX FUND0.84%
Ultra-Small Company Fund0.46%
Fidelity Extended Market Index Fund0.43%
iShares Micro-Cap ETF0.27%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.12%
EA Bridgeway Omni Small-Cap Value ETF0.08%
Fidelity Nasdaq Composite Index Fund0.06%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.05%

OakChart. FBIO. Cached 15 minutes.

Some panels did not load: insider.